PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in Preclinical Tumor Model. The combination therapies resulted in robust anti-tumor effects and showed significant improvement in survival compared to either therapy alone. Preclinical TERT study results were detailed in a paper published in the most recent edition of Molecular Therapy entitled, “Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT,” by Inovio and its collaborators at the Wistar Institute. Dr. J. Joseph […]
This post first appeared on Bloggerwave Inc. Is In The StockGuru Spotlight For October 22, 2010 | StockGuru SmallCap Alerts On Penny Stocks, please read the originial post: here